☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Exact name of registrant as specified in its charter) (State or other jurisdiction of OR TEVA PHARMACEUTICAL INDUSTRIES LIMITED ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-16174 incorporation or or ...

Potential to be first long-acting olanzapine with a favorable safety profile 官 H2 2026 - Phase III results $2.5bn Anti-TL1A (TEV-'574) H2 2024 – Phase II interim $28bn 14 | Target Updates Access programs launched (of 8 - 2025 target) cumulative regulatory submissions* (51% of 2025 target) reduction in scope 1 and 2 greenhouse gas emissions (52% of 2030 target) of employees trained on compliance policies** Winner: Best Company for Sustainability Reporting Finalist: Best Company for Social Responsibility dose ...

https://reportify-1252068037.cos.ap-beijing.myqcloud.com/media/production/s_m_content_8f541dc8773d15853a01aaed8cf3791f.html ...

Sven Dethlefs - Head, North America Commercial Hello, and welcome to the Q2 2023 Teva Pharmaceutical Industries Limited Earnings Conference Call. My name is Alex. I'll be coordinating the call today. [Operator instructions]. Jason Gerberry - Bank of America Chris Schott - J.P. Morgan Teva Pharmaceutical Industries Limited (NYSE:TEVA) Q2 2023 Earnings Conference Call August 2, 2023 8:00 AM ET Company Participants Richard Francis - President & CEO Ran Meir - IR Conference Call Participants Umer Raffat - Everc ...

Free Cash Flow by Quarters Free cash flow includes cash flow from operating activities, beneficial interest collected in exchange for securitized accounts receivables, proceeds from divestitures of businesses and other assets, net of cash used for capital investment. | 29 | 20.0 19.0 18.4 18.5 18.0 4.8 4.7 4.6 4.4 4.4 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 | 30 | 1.0* 1.6 1.8 3.4 3.0 2.1 2.5 1.6 1.0 0.8 2.0 23 24 25 26 27 28 29 30 31 … 36 … 46 | --- | --- | --- | --- | |------------------------------------ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-16174 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) Israel Not Applicable (State or other jurisdiction of (IRS Employer incorp ...

Ran Meir - SVP, Investor Relations Richard Francis - President & CEO Eli Kalif - CFO Eric Hughes - Chief Medical Officer, Head of Research and Development Sven Dethlefs - Head, North America Commercial Operator Ran Meir Richard Francis We have an emerging innovative business, primarily driven by AUSTEDO and AJOVY, but recently about to be supported by UZEDY, our long-acting schizophrenia product, and this is gonna fuel continued growth going Now coming to our core business, our core generics business. This ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-16174 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) Israel Not Applicable (State or other jurisdiction of (IRS Employer incor ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Barclays Global Healthcare Conference March 14, 2023 10:15 AM ET Company Participants Eli Kalif - EVP and CFO Conference Call Participants Balaji Prasad - Barclays Balaji Prasad Good morning, everyone. My name is Balaji Prasad, I'm the Senior Analyst for the Barclays Specialty Pharmaceuticals coverage. For the next session of the day at the Barclays Annual Healthcare Conference. I have the pleasure of hosting Teva, and Eli Kalif, the Chief Financial Officer ...

Some amounts in this presentation may not add up due to rounding. All percentages have been calculated using unrounded amounts. − Significant foreign exchange headwinds on revenues: − Debt reduction continues; net debt reduced to $18.4 billion − Europerevenues up 9% in local currency, reflecting higher demand and successful new product launches, including generic Eliquis® * Compared to Q4 2021 ** Compared to FY 2021 | 5 | 54,832 0 10,000 20,000 30,000 40,000 50,000 60,000 Source: IQVIA US NPA Audit Source: ...